The content on this site is intended for healthcare professionals only
Dr John Mendelsohn, Dr Richard Schilsky and Dr Richard Buller discuss the need for more genomic research, the move towards more of a personalised style of medicine and how these fields are highlighted at the annual WIN Symposium in Paris.
The symposium will take place on the 10th to the 12th of July, 2013.
ecancerclub members are eligible for a discount on the registration fee for this conference, for more info click here.
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC
Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients
